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Why I Am Optimistic about My Post 
PhD-degree Life – A Commentary 
 
 
Sophia L. Johnson, MPH, PharmD 
 
ABSTRACT 
 Public health is an area where we will always need professionally-prepared people. Whereas some soon-to-be 
graduates are concerned about their future job prospects, others express optimism, undeterred by the economic 
downturn of the past five years and the funding challenges that currently burden higher education. Staying focused and 
finding the right niche may be the key to a successful future.  
Florida Public Health Review, 2013; 10, 12-13. 
I am not worried about my post-degree 
professional life. I intend to pursue a health services 
research position in an academic setting. Recent 
legislation and the adoption of expanded quality 
standards by a key government health insurers support 
the relevance of my specialized career path. The 
Patient Protection and Affordable Care Act (PPACA) 
was enacted in 2010 with provisions that include 
covering most uninsured Americans, eliminating 
unnecessary spending and treatment in the health care 
system as a whole, and particular, for Medicare 
beneficiaries (Davis et al, 2011). The PPACA also 
allowed for the establishment of the patient-centered 
outcome research institute (Patient-Centered Outcomes 
Research Institute [PCORI], 2013).  During the same 
time period, the Center for Medicare and Medicaid 
Services approved inflammatory bowel disease (IBD) 
specific quality metrics that were implemented in 2012 
(Centers for Medicare and Medicaid Services, 2012). 
The enactment of these landmark policies should 
improve healthcare access for millions of Americans 
while also redirecting or eliminating billions of dollars 
in wasteful spending in the healthcare system and 
improving the quality of care received.  These policies 
are of particular importance to my professional future.  
Specifically, I have been a clinical pharmacist for 20 
years with formal training in epidemiology for over a 
decade.  I have recently returned to academia for 
additional training in methodology to pursue a role as a 
health services researcher.  In my previous clinical role 
I worked with patients that had long-standing IBD 
requiring on-going specialized nutrition support at 
home, I subsequently wrote institutional drug policy 
for a major health system to help manage IBD and 
other illnesses. Patients requiring parenteral or enteral 
nutrition therapies cannot absorb nutrients 
adequately—this health state is frequently due to 
repeat surgical interventions as a means to eliminate 
inflamed sections of bowel and control disease 
symptoms.  For the vast majority of IBD patients 
surgical interventions are a negative health outcome as 
are hospitalizations and maintenance doses of steroids.  
National treatment guidelines affirm that IBD should 
be managed primarily in an ambulatory setting with 
steroid sparing pharmacotherapeutic regimens 
(Kombuth & Sachar, 2010; Lichtenstein et al, 2009).  
My prior clinical responsibilities made me aware of the 
need for drug therapy optimization in IBD patients as 
well as the sequelae associated with suboptimal 
treatment.  These experiences led to my desire to 
contribute to the data available to inform drug therapy 
selection and policy development that would ensure 
consistent and appropriate management of these 
patients. 
IBD is estimated to cost $6.3 billion annually in 
the United States (Kappelman et al, 2008).  Biologic 
therapies, though expensive ($2000-$4000/month) 
have been shown to improve treatment outcomes in 
younger IBD patients with moderate to severe disease 
(Kappelman et al, 2008; Leombrunto et al, 2011; 
Lichtenstein et al, 2005; Park & Bass, 2011).  
Specifically, they have been shown to decrease the 
need for surgeries, hospitalizations and chronic 
corticosteroid utilization. IBD patients have normal or 
near normal life expectancies; there is a bimodal peak 
onset and older individuals are living longer, and 
therefore, IBD prevalence in older individuals is 
increasing. This trend is important because the clinical 
drug trials, cost-effectiveness analyses and efficacy 
studies conducted with biologics in IBD have not been 
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done in patients’ ≥65 years old. Therefore, although 
IBD is an expensive disease state and older patients are 
more complicated to manage due to numerous 
comorbidities and polypharmacy, appropriate drug 
selection and associated treatment outcomes in older 
IBD patients represent a significant gap in our 
knowledge. Drug utilization trends and associated 
treatment outcomes in older IBD patients is the current 
focus of my research program. 
Diseases that are difficult and expensive to 
manage that are increasing in prevalence and that are 
amenable to more cost-effective approaches to achieve 
improved patient-centered outcomes are prime targets 
for PCORI funding.  PCORI (2013) has awarded $88.6 
million to 51 projects over 3 years and even without 
congressional reauthorization, the institute is funded 
through 2019.   Robust health services research, 
population health, pharmacoepidemiology and health 
outcomes research programs located within academic 
institutions and departments within institutes are 
committed to conducting the research required to 
achieve better health and healthcare outcomes in these 
types of expensive, difficult to manage populations. 
These academic departments and institutes need to hire 
individuals who have the ability to conduct this 
research and who have the credentials to compete for 
PCORI and other outcomes research funding. 
Although total research dollars have been 
decreasing over the last several decades and funds and 
research positions have become increasingly 
competitive, I believe that the need to improve 
healthcare access, quality, and spending has not only 
necessitated the PPACA legislation, but also, the need 
for researchers with diverse backgrounds equipped to 
ask questions in unique ways.  As a policy-oriented, 
clinically-trained pharmacist and health services 
outcomes researcher, I will be well situated to 
contribute to this essential body of research. Therefore, 
I believe that my post-degree professional life will be 
rewarding and beneficial to society. 
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